ClinicalTrials.gg
CompletedNCT03173560Updated Apr 1, 2025Results posted

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

A Phase 2 interventional study of lenvatinib and everolimus in Renal Cell Carcinoma, sponsored by Eisai Inc.. Completed at 93 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing lenvatinib in Carcinoma, Renal Cell — 13 open to participants now, 17 under way, 2 of them phase 3. lenvatinib · Carcinoma, Renal Cell.

Enrollment
3rd of 30
343 · median 30
Started
2017
the only one that year
Phase 2
22 of 30
10 open now
Registered
4th of 30
by date
Lead sponsor
3 of 30
Eisai Inc.

Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 22 in phase 2, and was the 4th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

13 of the 30 studies testing lenvatinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing lenvatinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Study E7080-G000-218 is a Randomized, open-label (formerly Double-blind), Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg (based on treatment-emergent intolerable Grade 2, or any greater than or equal to (>=) Grade 3 adverse events (AEs) in the first 24 weeks after randomization).

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Renal Cell Carcinoma
  • lenvatinib
  • everolimus
  • E7080
  • VEGF-targeted treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmation of predominant clear cell renal cell carcinoma (RCC) (original tissue diagnosis of RCC is acceptable)
  • Documented evidence of advanced RCC
  • One prior disease progression episode on or after vascular endothelial growth factor (VEGF)-targeted treatment (for example, but not limited to, sunitinib, sorafenib, pazopanib, cabozantinib, bevacizumab, axitinib, vatalanib, AV951/tivozanib) administered for the treatment of RCC. Prior programmed cell death protein 1 ()/programmed death-ligand 1 (PD-L1) treatment in addition to 1 prior VEGF-targeted treatment is allowed.
  • At least 1 measurable target lesion according to (RECIST 1.1) meeting the following criteria:

    • Lymph node (LN) lesion that measures at least 1 dimension as >=1.5 centimeter (cm) in the short axis;
    • Non-nodal lesion that measures >=1.0 cm in the longest diameter;
    • The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST 1.1 to be deemed a target lesion.
  • Male or female participants age >=18 years (or any age >=18 years if that age is considered to be an adult per the local jurisdiction) at the time of
  • Performance Status (KPS) of >=70
  • Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to (\<=) 150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1
  • Adequate renal function defined as calculated >=30 milliliters per minute (mL/min) per the Cockcroft and Gault formula
  • Adequate bone marrow function defined by:

    • (ANC) >=1500/millimeters cubed (mm\^3) (>=1.5*10\^9/Liters [L]);
    • >=100,000/mm\^3 (>=100*10\^9/L);
    • >=9 grams per deciliter (g/dL)
  • Adequate blood coagulation function defined by (INR) \<=1.5 (except for participants on warfarin therapy where INR must be \<=3.0 prior to randomization)
  • Adequate liver function defined by:

    • Total \<=1.5 times the (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome;
    • Alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) \<=3* the ULN (in the case of liver \<=5* the ULN). Participants with bone metastases with ALP values greater than 3 times can be included.
  • Participant must voluntarily agree to provide written informed consent
  • Participant must be willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • More than 1 prior VEGF-targeted treatment for advanced RCC
  • Participants with Central Nervous System (CNS) are not eligible, unless they have completed local therapy for at least 4 weeks and have discontinued the use of for this indication or are on a tapering regimen of corticosteroids (defined as \<=10 mg prednisolone equivalent) before starting treatment in this study. Any signs (example, radiologic) or symptoms of must be stable for at least 4 weeks before starting study treatment.
  • Active (except for RCC or definitively treated basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months
  • Any anti-cancer treatment (except for radiation therapy) within 21 days, or any agent within 30 days prior to the first dose of study drug; participants should have recovered from any toxicity related to previous anti-cancer treatment to Common Toxicity Criteria (CTC) grade 0 or 1.
  • Prior radiation therapy within 21 days prior to the start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start
  • Known intolerance to study drug (or any of the ) and/or known to rapamycins (example, sirolimus, everolimus, temsirolimus) or any of the excipients
  • Participants with proteinuria greater than (>) 1+ on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein >=1 g/24 hour will be ineligible.
  • Fasting total cholesterol ˃300 mg/dL (or ˃7.75 millimoles [mmol]/L) and/or fasting triglycerides level ˃2.5* the . Note: these participants can be included after initiation or adjustment of lipid-lowering medication.
  • Uncontrolled diabetes as defined by fasting glucose >1.5 times the ULN. Note: these participants can be included after initiation or adjustment of glucose-lowering medication.
  • Prolongation of corrected (QTc) interval to >480 milliseconds (ms)
  • Participants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
  • Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
  • Bleeding or thrombotic disorders or participants at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels (example, carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.
  • hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
  • Significant cardiovascular impairment within 6 months prior to the first dose of study drug; history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or stroke, or cardiac arrhythmia associated with significant cardiovascular impairment or (LVEF) below the institutional normal range as determined by screening multigated acquisition (MUGA) scan or echocardiogram.
  • Active infection (any infection requiring systemic treatment)
  • Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study
  • Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 International Units per Liter [IU/L] or equivalent units of β-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  • Females of who (Note: all females will be considered to be of childbearing potential unless they are [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing].):

    • do not agree to use a highly effective method of for the entire study period and for up to 8 weeks after study drug discontinuation, that is:

      • total abstinence (if it is their preferred and usual lifestyle)
      • an intrauterine device (IUD) or hormone releasing system (IUS)
      • a contraceptive implant
      • an oral contraceptive (with additional barrier method) (Note: Participants must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study.) OR
    • do not have a vasectomized partner with confirmed azoospermia

For sites outside of the European Union, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double barrier methods of contraception, such as condom plus diaphragm or cervical/vault cap with spermicide.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Lenvatinib 14 mg plus everolimus 5 mg

    Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any \>= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to \[=\] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.

    Drug: lenvatinib · Drug: everolimus

  • Experimental
    Lenvatinib 18 mg plus everolimus 5 mg

    Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.

    Drug: lenvatinib · Drug: everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate at Week 24 (ORR24W)

    ORR24W was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at the Week 24 (after randomization) time point, during treatment or within 28 days after the last dose date but on or prior to the start of new anticancer therapy based on investigator assessment according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR: defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response.

    Time frame: At Week 24

  2. Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks

    TEAE was defined as an adverse event (AE) with an onset that had occurred after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

    Time frame: Up to Week 24

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of the first documentation of PD by investigator assessment or date of death, whichever occurred first according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter (SOD) of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% confidence interval (CI). As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to date of data cutoff for the primary analysis (up to 29 months)

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a BOR of CR or PR at the at the end of treatment based on investigator assessment according to RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: From date of randomization up to first documentation of PD or date of death, whichever occurred first or up to the date of data cut off for the primary analysis (up to 29 months)

  3. Number of Participants With TEAEs and Serious TEAEs

    TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A serious adverse event (SAE) was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.

    Time frame: From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)

  4. Percentage of Participants Who Discontinued Treatment Due to Toxicity

    Percentage of participants who discontinued treatment due to toxicity, defined as the percentage of participants who discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to NCI-CTCAE v4.03.

    Time frame: From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)

  5. Time to Treatment Failure Due to Toxicity

    Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to CTCAE v4.03. As planned, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: From the date of randomization to the date of discontinuation of study treatment due to TEAEs, or date of data cut off for the primary analysis (up to 29 months)

  6. Plasma Concentration of Lenvatinib

    PK sparse sampling was performed. As planned, the post-dose plasma sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  7. Whole Blood Concentration of Everolimus

    PK sparse sampling was performed. As planned, the post-dose whole blood sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  8. Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction

    Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib CL/F value was derived from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  9. Model Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction

    Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  10. Model Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction

    Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus CL/F value was derived from the final PK model.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  11. Model Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction

    Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)

  12. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. In the absence of confirmation of death, participants will be censored either at the date that the participant was last known to be alive or the date of data cutoff for the primary analysis, whichever comes earlier. Median OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: From the date of randomization until the date of death from any cause, or up to date of data cut off for the primary analysis (up to 29 months)

  13. Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores

    The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)

  14. HRQoL Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Scores

    The EORT QLQ-C30 consisted of 30 questions comprising 9 multiple-item scales and 6 single items. Multiple-item scales of QLQ-C30 consisted of 5 functional scales (physical, role, emotional, cognitive, and social) and 3 symptom scales (fatigue, nausea and vomiting, pain) and a global health status/QOL score. Six single-item scales of QLQ-C30 involved dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. First 28 questions used a 4-point scale (1 = Not at all to 4 = Very much); and last 2 questions used a 7-point scale (1 = Very poor to 7 = Excellent). Scores for all scales range from 0 to 100. For the overall HRQoL and functioning scales, a higher score was correlated with better HRQoL, whereas a higher score for symptom scales represented worse HRQoL. As pre-specified in protocol, data for secondary outcome measure was collected and analyzed till primary analysis only.

    Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)

  15. HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Index Score and Visual Analogue Scale (VAS)

    The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. The EQ-5D index was calculated by applying preference-based weights (tariffs) to the scores of the five health state dimensions. Index values can range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).

    Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)

  16. Progression-free Survival After Next Line of Therapy (PFS2)

    PFS2, defined as the time from randomization to the date of PD after next line of therapy or death from any cause, whichever occurred first based on investigator assessment according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS2 was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% CI. As pre-specified in protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

    Time frame: From the time of randomization to the date of PD after next line of therapy or death from any cause or the date of data cutoff for the primary analysis, whichever occurs first (up to 29 months)

07

Results

Posted Mar 5, 2021

Participant flow

Participants took part in the study at 82 investigative sites in Australia, Korea, Taiwan, Czech, Poland, Romania, Russia, Finland, Greece, Italy, Netherlands, Portugal, Spain, United Kingdom, Canada and the United States from 17 August 2017 to 20 June 2024.

Participant flow — Overall Study
MilestoneLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Started172171
Treated participants172169
Safety set173168
Completed91101
Not completed8170
Withdrew: Death7060
Withdrew: Lost to follow-up14
Withdrew: Withdrawal by subject105
Withdrew: Other01

Outcome measures

PrimaryObjective Response Rate at Week 24 (ORR24W)

ORR24W was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at the Week 24 (after randomization) time point, during treatment or within 28 days after the last dose date but on or prior to the start of new anticancer therapy based on investigator assessment according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR: defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Objective Response Rate at Week 24 (ORR24W)
percentage of participantsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Objective Response Rate at Week 24 (ORR24W)32.1 (24.7 to 39.4)34.8 (27.3 to 42.3)
Statistical analysis
  • Lenvatinib 14 mg + Everolimus 5 mg vs Lenvatinib 18 mg + Everolimus 5 mg · Cochran-Mantel-Haenszel · p = 0.2676 · Odds ratio (or): 0.88 · 90% CI 0.59 to 1.32
PrimaryPercentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks

TEAE was defined as an adverse event (AE) with an onset that had occurred after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks
percentage of participantsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks82.8 (76.9 to 88.7)79.6 (73.2 to 86.0)
Statistical analysis
  • Lenvatinib 14 mg + Everolimus 5 mg vs Lenvatinib 18 mg + Everolimus 5 mg · Cochran-Mantel-Haenszel · p = 0.4763 · Difference: 3.2 · 95% CI -5.5 to 11.9
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of the first documentation of PD by investigator assessment or date of death, whichever occurred first according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter (SOD) of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% confidence interval (CI). As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to date of data cutoff for the primary analysis (up to 29 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Progression-free Survival (PFS)11.1 (9.0 to 12.9)14.7 (11.1 to 20.3)
Statistical analysis
  • Lenvatinib 14 mg + Everolimus 5 mg vs Lenvatinib 18 mg + Everolimus 5 mg · Hazard ratio (hr): 1.42 · 90% CI 1.08 to 1.86
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a BOR of CR or PR at the at the end of treatment based on investigator assessment according to RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
From date of randomization up to first documentation of PD or date of death, whichever occurred first or up to the date of data cut off for the primary analysis (up to 29 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Objective Response Rate (ORR)34.6 (27.1 to 42.1)40.6 (32.9 to 48.4)
Statistical analysis
  • Lenvatinib 14 mg + Everolimus 5 mg vs Lenvatinib 18 mg + Everolimus 5 mg · Odds ratio (or): 0.77 · 90% CI 0.52 to 1.14
SecondaryNumber of Participants With TEAEs and Serious TEAEs

TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A serious adverse event (SAE) was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.

Time frame:
From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and Serious TEAEs
ParticipantsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Participants With TEAEs173167
Participants With Serious TEAEs9287
SecondaryPercentage of Participants Who Discontinued Treatment Due to Toxicity

Percentage of participants who discontinued treatment due to toxicity, defined as the percentage of participants who discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to NCI-CTCAE v4.03.

Time frame:
From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Treatment Due to Toxicity
percentage of participantsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Percentage of Participants Who Discontinued Treatment Due to Toxicity17.425.1
SecondaryTime to Treatment Failure Due to Toxicity

Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to CTCAE v4.03. As planned, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
From the date of randomization to the date of discontinuation of study treatment due to TEAEs, or date of data cut off for the primary analysis (up to 29 months)
Reported as:
Median · months
Time to Treatment Failure Due to Toxicity
monthsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Time to Treatment Failure Due to Toxicity3.15 (0.5 to 12.7)5.70 (0.8 to 24.6)
SecondaryPlasma Concentration of Lenvatinib

PK sparse sampling was performed. As planned, the post-dose plasma sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma Concentration of Lenvatinib
nanogram per milliliter (ng/mL)Lenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Cycle 1 Day 1: 0.5-4 hours post-dose57.9 ± 96.5482.3 ± 119.89
Cycle 1 Day 1: 6-10 hours post-dose136.3 ± 66.53193.7 ± 93.08
Cycle 1 Day 15: Pre-dose53.7 ± 62.3164.0 ± 59.71
Cycle 1 Day 15: 0.5-4 hours post-dose99.6 ± 102.54133.4 ± 125.65
Cycle 1 Day 15: 6-10 hours post-dose177.8 ± 89.42236.2 ± 135.21
Cycle 2 Day 1: Pre-dose42.8 ± 42.8450.6 ± 46.06
Cycle 2 Day 1: 2-12 hours post-dose172.8 ± 130.90190.3 ± 114.85
SecondaryWhole Blood Concentration of Everolimus

PK sparse sampling was performed. As planned, the post-dose whole blood sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · ng/mL
Whole Blood Concentration of Everolimus
ng/mLLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Cycle 1 Day 1: 0.5-4 hours post-dose18.3 ± 15.8918.6 ± 16.39
Cycle 1 Day 1: 6-10 hours post-dose9.2 ± 6.608.4 ± 5.64
Cycle 1 Day 15: Pre-dose8.4 ± 4.847.4 ± 5.51
Cycle 1 Day 15: 0.5-4 hours post-dose23.7 ± 15.4123.4 ± 16.96
Cycle 1 Day 15: 6-10 hours post-dose14.3 ± 5.8314.3 ± 9.22
Cycle 2 Day 1: Pre-dose7.8 ± 5.445.9 ± 4.02
Cycle 2 Day 1: 2-12 hours post-dose22.9 ± 12.6719.5 ± 9.74
SecondaryModel Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction

Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib CL/F value was derived from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · liter per hour (L/h)
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction
liter per hour (L/h)Lenvatinib 18 mgLenvatinib 18 mg + Everolimus 5 mg
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction6.37 ± 2.015.77 ± 2.01
SecondaryModel Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction

Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Model Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction
nanogram*hour per milliliter (ng*h/mL)Lenvatinib 18 mgLenvatinib 18 mg + Everolimus 5 mg
Model Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction3693 ± 12954350 ± 2934
SecondaryModel Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction

Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus CL/F value was derived from the final PK model.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · liter per hour (L/h)
Model Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction
liter per hour (L/h)Everolimus 10 mgLenvatinib + Everolimus 5 mg
Model Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction22.3 ± 10.519.4 ± 7.9
SecondaryModel Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction

Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Reported as:
Mean · ng*hour/mL
Model Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction
ng*hour/mLEverolimus 10 mgLenvatinib + Everolimus 5 mg
Model Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction507.4 ± 176.6305.5 ± 174.0
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. In the absence of confirmation of death, participants will be censored either at the date that the participant was last known to be alive or the date of data cutoff for the primary analysis, whichever comes earlier. Median OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
From the date of randomization until the date of death from any cause, or up to date of data cut off for the primary analysis (up to 29 months)
Reported as:
Median · months
Overall Survival (OS)
monthsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Overall Survival (OS)27.0 (18.3 to NA)NA (23.8 to NA)
SecondaryHealth-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores

The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
Reported as:
Mean · score on a scale
Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores
score on a scaleLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Baseline29.69 ± 4.81929 ± 5.886
Cycle 2 Day 128.43 ± 5.26928.31 ± 5.162
Cycle 3 Day 128.26 ± 5.34428.80 ± 5.455
Cycle 4 Day 127.97 ± 5.52429.11 ± 5.183
Cycle 5 Day 128 ± 5.68029.14 ± 5.081
Cycle 6 Day 128.63 ± 5.18529.46 ± 5.107
Cycle 7 Day 128.31 ± 5.48629.58 ± 4.803
Cycle 8 Day 128.36 ± 6.20429.85 ± 4.610
Cycle 9 Day 128.58 ± 5.56229.84 ± 5.005
Cycle 10 Day 129.10 ± 5.29430.70 ± 4.297
Cycle 11 Day 129.56 ± 5.03530.09 ± 5.316
Cycle 12 Day 129.34 ± 5.14930.75 ± 5.127
Cycle 13 Day 129.26 ± 4.85130.93 ± 4.201
Cycle 14 Day 129.81 ± 4.75231.06 ± 4.830
Cycle 15 Day 130.09 ± 5.12130.52 ± 4.417
Cycle 16 Day 129.93 ± 5.29330.91 ± 4.704
Cycle 17 Day 129.36 ± 5.23331.52 ± 4.875
Cycle 18 Day 129.81 ± 4.29331.41 ± 4.639
Cycle 19 Day 128.48 ± 6.21630.82 ± 4.469
Cycle 20 Day 128.77 ± 6.05830.69 ± 4.575
Cycle 21 Day 129.35 ± 4.70732 ± 3.243
Cycle 22 Day 130.32 ± 4.97830.59 ± 5.168
Cycle 23 Day 130.53 ± 3.99830.29 ± 5.544
Cycle 24 Day 129.47 ± 5.04131.58 ± 3.977
Cycle 25 Day 127.92 ± 6.38831.69 ± 4.270
Cycle 26 Day 128.75 ± 4.86229.82 ± 6.422
Cycle 27 Day 129.83 ± 5.34532.86 ± 2.854
Cycle 28 Day 130.50 ± 4.43533.67 ± 1.862
Cycle 29 Day 129.50 ± 4.35933.40 ± 1.342
Cycle 30 Day 130.75 ± 4.03136
Cycle 31 Day 131—
Off-treatment Visit27.42 ± 5.95327.86 ± 6.500
SecondaryHRQoL Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Scores

The EORT QLQ-C30 consisted of 30 questions comprising 9 multiple-item scales and 6 single items. Multiple-item scales of QLQ-C30 consisted of 5 functional scales (physical, role, emotional, cognitive, and social) and 3 symptom scales (fatigue, nausea and vomiting, pain) and a global health status/QOL score. Six single-item scales of QLQ-C30 involved dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. First 28 questions used a 4-point scale (1 = Not at all to 4 = Very much); and last 2 questions used a 7-point scale (1 = Very poor to 7 = Excellent). Scores for all scales range from 0 to 100. For the overall HRQoL and functioning scales, a higher score was correlated with better HRQoL, whereas a higher score for symptom scales represented worse HRQoL. As pre-specified in protocol, data for secondary outcome measure was collected and analyzed till primary analysis only.

Time frame:
At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
Reported as:
Mean · score on a scale
HRQoL Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Scores
score on a scaleLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Global Health Status/QoL Score; Baseline63.35 ± 22.02063.58 ± 21.340
Global Health Status/QoL Score; Cycle 2 Day 158.60 ± 21.23460.93 ± 20.280
Global Health Status/QoL Score; Cycle 3 Day 156.43 ± 24.06561.85 ± 20.202
Global Health Status/QoL Score; Cycle 4 Day 158.71 ± 19.75462.62 ± 19.641
Global Health Status/QoL Score; Cycle 5 Day 159.38 ± 21.67063.76 ± 20.339
Global Health Status/QoL Score; Cycle 6 Day 158.75 ± 21.02863.73 ± 19.756
Global Health Status/QoL Score; Cycle 7 Day 158.72 ± 20.13462.54 ± 20.153
Global Health Status/QoL Score; Cycle 8 Day 158.68 ± 20.40962.11 ± 20.271
Global Health Status/QoL Score; Cycle 9 Day 158.97 ± 18.72663.77 ± 20.429
Global Health Status/QoL Score; Cycle 10 Day 163.13 ± 19.61266.44 ± 19.012
Global Health Status/QoL Score; Cycle 11 Day 160.87 ± 18.70565.86 ± 21.173
Global Health Status/QoL Score; Cycle 12 Day 157.81 ± 18.89166.94 ± 18.409
Global Health Status/QoL Score; Cycle 13 Day 159.39 ± 19.04768.94 ± 18.388
Global Health Status/QoL Score; Cycle 14 Day 161.56 ± 17.49870.35 ± 15.605
Global Health Status/QoL Score; Cycle 15 Day 162.98 ± 16.79566.83 ± 16.955
Global Health Status/QoL Score; Cycle 16 Day 161.59 ± 17.56764.54 ± 19.386
Global Health Status/QoL Score; Cycle 17 Day 160.88 ± 16.88267.71 ± 18.794
Global Health Status/QoL Score; Cycle 18 Day 159.68 ± 16.25868.38 ± 17.859
Global Health Status/QoL Score; Cycle 19 Day 158.33 ± 19.74766.67 ± 15.215
Global Health Status/QoL Score; Cycle 20 Day 158.95 ± 18.47966.40 ± 15.736
Global Health Status/QoL Score; Cycle 21 Day 157.05 ± 18.36271.13 ± 15.463
Global Health Status/QoL Score; Cycle 22 Day 162.72 ± 14.53266.05 ± 17.438
Global Health Status/QoL Score; Cycle 23 Day 160 ± 15.49466.67 ± 14.948
Global Health Status/QoL Score; Cycle 24 Day 164.44 ± 17.38565.79 ± 18.818
Global Health Status/QoL Score; Cycle 25 Day 158.33 ± 16.66769.79 ± 14.868
Global Health Status/QoL Score; Cycle 26 Day 159.38 ± 15.06460.90 ± 18.442
Global Health Status/QoL Score; Cycle 27 Day 159.72 ± 18.57271.43 ± 18.545
Global Health Status/QoL Score; Cycle 28 Day 158.33 ± 21.51777.78 ± 13.608
Global Health Status/QoL Score; Cycle 29 Day 156.25 ± 18.47875 ± 16.667
Global Health Status/QoL Score; Cycle 30 Day 154.17 ± 15.95766.67
Global Health Status/QoL Score; Cycle 31 Day 133.33—
Global Health Status/QoL Score; Off-treatment Visit51.04 ± 23.13356.05 ± 22.363
Physical Functioning Score; Baseline76.36 ± 19.28276.60 ± 21.855
Physical Functioning Score; Cycle 2 Day 173.54 ± 19.85775.38 ± 19.706
Physical Functioning Score; Cycle 3 Day 172.74 ± 21.22776.15 ± 19.160
Physical Functioning Score; Cycle 4 Day 170.90 ± 20.87375.40 ± 20.155
Physical Functioning Score; Cycle 5 Day 172.80 ± 19.28477.85 ± 18.342
Physical Functioning Score; Cycle 6 Day 172.17 ± 21.69477.76 ± 18.562
Physical Functioning Score; Cycle 7 Day 173.02 ± 20.76978.41 ± 18.034
Physical Functioning Score; Cycle 8 Day 172.77 ± 20.42279.11 ± 17.707
Physical Functioning Score; Cycle 9 Day 174.54 ± 19.38980.60 ± 16.041
Physical Functioning Score; Cycle 10 Day 175.06 ± 18.90881.20 ± 16.271
Physical Functioning Score; Cycle 11 Day 173.72 ± 18.07381.13 ± 16.638
Physical Functioning Score; Cycle 12 Day 175.52 ± 17.08083.01 ± 15.254
Physical Functioning Score; Cycle 13 Day 174.55 ± 17.87480.24 ± 16.873
Physical Functioning Score; Cycle 14 Day 175.78 ± 16.92582.39 ± 16.387
Physical Functioning Score; Cycle 15 Day 175.45 ± 16.62980.92 ± 17.283
Physical Functioning Score; Cycle 16 Day 173.46 ± 17.12981.74 ± 15.982
Physical Functioning Score; Cycle 17 Day 171.85 ± 17.89682.33 ± 15.657
Physical Functioning Score; Cycle 18 Day 175.48 ± 17.83881.52 ± 16.135
Physical Functioning Score; Cycle 19 Day 176.67 ± 15.77181.57 ± 16.002
Physical Functioning Score; Cycle 20 Day 173.09 ± 22.07182.80 ± 13.854
Physical Functioning Score; Cycle 21 Day 174.62 ± 18.66884.29 ± 12.335
Physical Functioning Score; Cycle 22 Day 180.35 ± 14.48382.72 ± 15.164
Physical Functioning Score; Cycle 23 Day 179.56 ± 14.35781.39 ± 17.248
Physical Functioning Score; Cycle 24 Day 177.33 ± 16.67683.86 ± 13.755
Physical Functioning Score; Cycle 25 Day 172.78 ± 15.68884.17 ± 15.753
Physical Functioning Score; Cycle 26 Day 176.67 ± 6.17271.79 ± 29.833
Physical Functioning Score; Cycle 27 Day 176.67 ± 6.99285.71 ± 16.523
Physical Functioning Score; Cycle 28 Day 178.33 ± 3.33390 ± 15.635
Physical Functioning Score; Cycle 29 Day 178.33 ± 3.33386.67 ± 16.330
Physical Functioning Score; Cycle 30 Day 176.67 ± 3.849100
Physical Functioning Score; Cycle 31 Day 180—
Physical Functioning Score; Off-treatment Visit64.50 ± 25.89170.41 ± 25.139
Role Functioning Score; Baseline73.78 ± 27.47175.72 ± 27.932
Role Functioning Score; Cycle 2 Day 168.25 ± 27.95169.33 ± 27.449
Role Functioning Score; Cycle 3 Day 167 ± 28.13672.18 ± 25.630
Role Functioning Score; Cycle 4 Day 166.67 ± 27.99373.60 ± 26.169
Role Functioning Score; Cycle 5 Day 167.32 ± 28.47972.44 ± 25.143
Role Functioning Score; Cycle 6 Day 168.16 ± 27.24573.75 ± 27.557
Role Functioning Score; Cycle 7 Day 166.51 ± 27.42473.97 ± 25.205
Role Functioning Score; Cycle 8 Day 168.20 ± 27.71275.60 ± 26.139
Role Functioning Score; Cycle 9 Day 167.58 ± 26.10175.91 ± 25.242
Role Functioning Score; Cycle 10 Day 168.52 ± 27.13176.89 ± 24.027
Role Functioning Score; Cycle 11 Day 169.57 ± 25.23779.11 ± 23.691
Role Functioning Score; Cycle 12 Day 170.51 ± 24.78580.91 ± 22.953
Role Functioning Score; Cycle 13 Day 169.64 ± 24.43480 ± 24.721
Role Functioning Score; Cycle 14 Day 171.09 ± 24.24281.13 ± 23.121
Role Functioning Score; Cycle 15 Day 172.73 ± 22.18474.84 ± 25.685
Role Functioning Score; Cycle 16 Day 170.33 ± 23.42679.08 ± 21.272
Role Functioning Score; Cycle 17 Day 165.74 ± 22.86883.75 ± 18.292
Role Functioning Score; Cycle 18 Day 167.74 ± 20.60982.35 ± 22.073
Role Functioning Score; Cycle 19 Day 167.28 ± 28.30077.45 ± 23.883
Role Functioning Score; Cycle 20 Day 170.37 ± 23.26679.57 ± 24.612
Role Functioning Score; Cycle 21 Day 169.23 ± 21.95681.55 ± 19.948
Role Functioning Score; Cycle 22 Day 175.44 ± 20.31377.78 ± 22.169
Role Functioning Score; Cycle 23 Day 173.33 ± 25.04079.86 ± 23.560
Role Functioning Score; Cycle 24 Day 178.89 ± 16.01983.33 ± 19.245
Role Functioning Score; Cycle 25 Day 177.78 ± 17.88582.29 ± 23.936
Role Functioning Score; Cycle 26 Day 175 ± 12.59969.23 ± 31.066
Role Functioning Score; Cycle 27 Day 177.78 ± 13.60890.48 ± 16.265
Role Functioning Score; Cycle 28 Day 179.17 ± 15.95797.22 ± 6.804
Role Functioning Score; Cycle 29 Day 175 ± 9.62396.67 ± 7.454
Role Functioning Score; Cycle 30 Day 187.50 ± 15.957100
Role Functioning Score; Cycle 31 Day 166.67—
Role Functioning Score; Off-treatment Visit60.97 ± 31.79063.51 ± 31.656
Emotional Functioning Score; Baseline79.35 ± 19.70480.06 ± 19.729
Emotional Functioning Score; Cycle 2 Day 179.41 ± 19.46582.06 ± 19.167
Emotional Functioning Score; Cycle 3 Day 178.47 ± 21.64282.90 ± 19.314
Emotional Functioning Score; Cycle 4 Day 178.26 ± 18.85484.19 ± 18.517
Emotional Functioning Score; Cycle 5 Day 175.85 ± 21.76784.52 ± 15.766
Emotional Functioning Score; Cycle 6 Day 180.60 ± 18.70384.38 ± 18.365
Emotional Functioning Score; Cycle 7 Day 177.18 ± 19.57184.29 ± 16.356
Emotional Functioning Score; Cycle 8 Day 179.08 ± 19.74484.88 ± 18.215
Emotional Functioning Score; Cycle 9 Day 178.75 ± 22.12785.96 ± 17.512
Emotional Functioning Score; Cycle 10 Day 180.04 ± 19.44087.84 ± 15.433
Emotional Functioning Score; Cycle 11 Day 182.25 ± 20.55887.15 ± 16.247
Emotional Functioning Score; Cycle 12 Day 181.51 ± 19.15786.67 ± 15.358
Emotional Functioning Score; Cycle 13 Day 179.32 ± 17.90887.27 ± 15.783
Emotional Functioning Score; Cycle 14 Day 181.35 ± 16.78287.50 ± 17.110
Emotional Functioning Score; Cycle 15 Day 180.30 ± 18.33687.25 ± 15.398
Emotional Functioning Score; Cycle 16 Day 181.50 ± 17.43287.41 ± 14.935
Emotional Functioning Score; Cycle 17 Day 179.63 ± 19.66487.08 ± 16.118
Emotional Functioning Score; Cycle 18 Day 181.90 ± 15.33086.76 ± 16.555
Emotional Functioning Score; Cycle 19 Day 181.17 ± 15.94584.80 ± 18.403
Emotional Functioning Score; Cycle 20 Day 180.25 ± 17.92586.56 ± 17.437
Emotional Functioning Score; Cycle 21 Day 181.73 ± 15.27988.99 ± 14.174
Emotional Functioning Score; Cycle 22 Day 185.09 ± 16.09689.20 ± 15.644
Emotional Functioning Score; Cycle 23 Day 186.67 ± 15.36687.15 ± 15.922
Emotional Functioning Score; Cycle 24 Day 188.89 ± 14.31987.28 ± 13.712
Emotional Functioning Score; Cycle 25 Day 183.33 ± 18.11990.63 ± 12.500
Emotional Functioning Score; Cycle 26 Day 177.08 ± 23.03885.26 ± 23.362
Emotional Functioning Score; Cycle 27 Day 180.56 ± 16.38795.24 ± 12.599
Emotional Functioning Score; Cycle 28 Day 175 ± 16.667100 ± 0
Emotional Functioning Score; Cycle 29 Day 175 ± 16.667100 ± 0
Emotional Functioning Score; Cycle 30 Day 175 ± 16.667100
Emotional Functioning Score; Cycle 31 Day 166.67—
Emotional Functioning Score; Off-treatment Visit69.62 ± 27.30473.87 ± 25.145
Cognitive Functioning Score; Baseline87.91 ± 15.76489.51 ± 15.529
Cognitive Functioning Score; Cycle 2 Day 187.15 ± 15.66188.85 ± 18.025
Cognitive Functioning Score; Cycle 3 Day 184.45 ± 19.04987.47 ± 17.946
Cognitive Functioning Score; Cycle 4 Day 183.58 ± 19.46190.32 ± 13.692
Cognitive Functioning Score; Cycle 5 Day 183.99 ± 17.23987.43 ± 17.086
Cognitive Functioning Score; Cycle 6 Day 184.71 ± 16.88687.68 ± 18.470
Cognitive Functioning Score; Cycle 7 Day 182.40 ± 18.85587.94 ± 14.708
Cognitive Functioning Score; Cycle 8 Day 181.97 ± 21.22788.49 ± 16.380
Cognitive Functioning Score; Cycle 9 Day 183.70 ± 18.08487.68 ± 17.095
Cognitive Functioning Score; Cycle 10 Day 185.39 ± 17.94790.44 ± 13.747
Cognitive Functioning Score; Cycle 11 Day 184.06 ± 18.17688.89 ± 15.824
Cognitive Functioning Score; Cycle 12 Day 185.42 ± 16.40088.61 ± 17.758
Cognitive Functioning Score; Cycle 13 Day 183.93 ± 17.68589.70 ± 12.624
Cognitive Functioning Score; Cycle 14 Day 185.71 ± 18.63487.18 ± 16.375
Cognitive Functioning Score; Cycle 15 Day 184.85 ± 18.26483.99 ± 17.308
Cognitive Functioning Score; Cycle 16 Day 183.74 ± 18.06289.36 ± 13.649
Cognitive Functioning Score; Cycle 17 Day 182.87 ± 18.03389.58 ± 14.465
Cognitive Functioning Score; Cycle 18 Day 183.87 ± 17.99490.20 ± 15.417
Cognitive Functioning Score; Cycle 19 Day 180.25 ± 18.51189.22 ± 14.727
Cognitive Functioning Score; Cycle 20 Day 182.10 ± 17.25091.94 ± 12.073
Cognitive Functioning Score; Cycle 21 Day 181.41 ± 19.62388.10 ± 12.715
Cognitive Functioning Score; Cycle 22 Day 188.60 ± 14.75490.12 ± 12.454
Cognitive Functioning Score; Cycle 23 Day 183.33 ± 16.66788.19 ± 14.311
Cognitive Functioning Score; Cycle 24 Day 184.44 ± 16.01992.11 ± 8.550
Cognitive Functioning Score; Cycle 25 Day 184.72 ± 15.00698.96 ± 4.167
Cognitive Functioning Score; Cycle 26 Day 189.58 ± 12.40092.31 ± 11.004
Cognitive Functioning Score; Cycle 27 Day 183.33 ± 14.90795.24 ± 12.599
Cognitive Functioning Score; Cycle 28 Day 191.67 ± 9.623100 ± 0
Cognitive Functioning Score; Cycle 29 Day 191.67 ± 9.623100 ± 0
Cognitive Functioning Score; Cycle 30 Day 187.50 ± 15.957100
Cognitive Functioning Score; Cycle 31 Day 183.33—
Cognitive Functioning Score; Off-treatment Visit75.21 ± 25.84680.41 ± 23.304
Social Functioning Score; Baseline77.29 ± 25.67878.29 ± 27.243
Social Functioning Score; Cycle 2 Day 173.46 ± 25.38677.15 ± 27.190
Social Functioning Score; Cycle 3 Day 172.04 ± 26.22977.19 ± 25.309
Social Functioning Score; Cycle 4 Day 171.43 ± 24.83777.33 ± 25.311
Social Functioning Score; Cycle 5 Day 171.78 ± 25.58979.63 ± 23.934
Social Functioning Score; Cycle 6 Day 170.80 ± 26.81278.71 ± 25.758
Social Functioning Score; Cycle 7 Day 171.70 ± 26.54477.30 ± 24.691
Social Functioning Score; Cycle 8 Day 170.24 ± 28.13979.04 ± 24.565
Social Functioning Score; Cycle 9 Day 172.16 ± 25.94678.62 ± 20.573
Social Functioning Score; Cycle 10 Day 172.43 ± 28.15685.14 ± 19.422
Social Functioning Score; Cycle 11 Day 173.91 ± 25.80185.19 ± 19.086
Social Functioning Score; Cycle 12 Day 176.56 ± 24.07383.89 ± 23.161
Social Functioning Score; Cycle 13 Day 172.92 ± 23.47683.94 ± 21.508
Social Functioning Score; Cycle 14 Day 172.79 ± 22.99783.97 ± 19.792
Social Functioning Score; Cycle 15 Day 172.73 ± 25.94281.37 ± 22.273
Social Functioning Score; Cycle 16 Day 173.17 ± 24.40380.80 ± 22.489
Social Functioning Score; Cycle 17 Day 170.37 ± 22.22280.42 ± 24.134
Social Functioning Score; Cycle 18 Day 176.88 ± 20.49382.84 ± 21.116
Social Functioning Score; Cycle 19 Day 174.07 ± 22.32980.88 ± 25.667
Social Functioning Score; Cycle 20 Day 175.31 ± 24.18381.72 ± 22.092
Social Functioning Score; Cycle 21 Day 173.72 ± 18.36282.14 ± 24.398
Social Functioning Score; Cycle 22 Day 179.82 ± 17.19482.10 ± 20.634
Social Functioning Score; Cycle 23 Day 182.22 ± 18.33083.33 ± 22.522
Social Functioning Score; Cycle 24 Day 183.33 ± 17.81784.21 ± 19.621
Social Functioning Score; Cycle 25 Day 187.50 ± 12.56384.38 ± 18.727
Social Functioning Score; Cycle 26 Day 183.33 ± 15.43076.92 ± 31.578
Social Functioning Score; Cycle 27 Day 180.56 ± 12.54695.24 ± 12.599
Social Functioning Score; Cycle 28 Day 183.33 ± 19.245100 ± 0
Social Functioning Score; Cycle 29 Day 179.17 ± 15.957100 ± 0
Social Functioning Score; Cycle 30 Day 170.83 ± 8.333100
Social Functioning Score; Cycle 31 Day 1100—
Social Functioning Score; Off-treatment Visit64.58 ± 31.41966.89 ± 32.453
Fatigue Score; Baseline31.32 ± 21.37931.76 ± 25.224
Fatigue Score; Cycle 2 Day 139.21 ± 22.17136.74 ± 23.665
Fatigue Score; Cycle 3 Day 140.09 ± 24.09536.62 ± 24.031
Fatigue Score; Cycle 4 Day 140.21 ± 23.50432.68 ± 23.829
Fatigue Score; Cycle 5 Day 137.54 ± 23.32935.17 ± 22.431
Fatigue Score; Cycle 6 Day 138.80 ± 23.24633.19 ± 23.696
Fatigue Score; Cycle 7 Day 138.06 ± 21.85030.79 ± 21.859
Fatigue Score; Cycle 8 Day 136.14 ± 22.85230.81 ± 23.268
Fatigue Score; Cycle 9 Day 135.90 ± 21.28130.80 ± 21.293
Fatigue Score; Cycle 10 Day 134.57 ± 22.63527.11 ± 20.278
Fatigue Score; Cycle 11 Day 132.37 ± 20.85127.46 ± 22.788
Fatigue Score; Cycle 12 Day 132.82 ± 20.26423.48 ± 21.302
Fatigue Score; Cycle 13 Day 135.52 ± 18.88225.05 ± 21.300
Fatigue Score; Cycle 14 Day 130.84 ± 21.42925.58 ± 20.276
Fatigue Score; Cycle 15 Day 128.03 ± 20.68228.98 ± 23.315
Fatigue Score; Cycle 16 Day 133.33 ± 22.36125.53 ± 20.581
Fatigue Score; Cycle 17 Day 133.33 ± 21.90225 ± 20.090
Fatigue Score; Cycle 18 Day 134.05 ± 22.02424.84 ± 19.546
Fatigue Score; Cycle 19 Day 137.04 ± 23.06127.45 ± 22.595
Fatigue Score; Cycle 20 Day 134.57 ± 19.81227.24 ± 22.192
Fatigue Score; Cycle 21 Day 134.19 ± 20.82823.02 ± 17.088
Fatigue Score; Cycle 22 Day 126.32 ± 18.59626.75 ± 20.033
Fatigue Score; Cycle 23 Day 126.67 ± 20.05329.17 ± 21.934
Fatigue Score; Cycle 24 Day 128.15 ± 20.08226.90 ± 17.496
Fatigue Score; Cycle 25 Day 133.33 ± 19.53425.69 ± 19.338
Fatigue Score; Cycle 26 Day 126.39 ± 17.75537.61 ± 28.160
Fatigue Score; Cycle 27 Day 127.78 ± 16.85120.63 ± 20.716
Fatigue Score; Cycle 28 Day 122.22 ± 15.71316.67 ± 19.563
Fatigue Score; Cycle 29 Day 122.22 ± 15.71315.56 ± 14.907
Fatigue Score; Cycle 30 Day 125 ± 16.66711.11
Fatigue Score; Cycle 31 Day 133.33—
Fatigue Score; Off-treatment Visit43.47 ± 28.17338.89 ± 28.977
Nausea and Vomiting Score; Baseline7.60 ± 17.2656.28 ± 14.510
Nausea and Vomiting Score; Cycle 2 Day 111.50 ± 18.2299.56 ± 17.943
Nausea and Vomiting Score; Cycle 3 Day 114.86 ± 24.0579.74 ± 18.219
Nausea and Vomiting Score; Cycle 4 Day 115.80 ± 21.38612.17 ± 18.906
Nausea and Vomiting Score; Cycle 5 Day 112.07 ± 17.01711.42 ± 18.270
Nausea and Vomiting Score; Cycle 6 Day 112.74 ± 19.21510.14 ± 18.996
Nausea and Vomiting Score; Cycle 7 Day 112.46 ± 18.6128.57 ± 13.696
Nausea and Vomiting Score; Cycle 8 Day 113.10 ± 21.83610.14 ± 15.508
Nausea and Vomiting Score; Cycle 9 Day 112.27 ± 20.0059.96 ± 17.306
Nausea and Vomiting Score; Cycle 10 Day 115.02 ± 22.2997.78 ± 16.287
Nausea and Vomiting Score; Cycle 11 Day 111.11 ± 18.0028.69 ± 15.394
Nausea and Vomiting Score; Cycle 12 Day 112.82 ± 19.0426.99 ± 14.645
Nausea and Vomiting Score; Cycle 13 Day 112.20 ± 18.9346.97 ± 13.867
Nausea and Vomiting Score; Cycle 14 Day 114.97 ± 21.8497.55 ± 16.527
Nausea and Vomiting Score; Cycle 15 Day 114.02 ± 20.6318.82 ± 15.038
Nausea and Vomiting Score; Cycle 16 Day 111.38 ± 19.8749.22 ± 15.467
Nausea and Vomiting Score; Cycle 17 Day 114.35 ± 22.9405 ± 13.183
Nausea and Vomiting Score; Cycle 18 Day 110.75 ± 22.5879.31 ± 15.457
Nausea and Vomiting Score; Cycle 19 Day 116.67 ± 27.3477.35 ± 15.457
Nausea and Vomiting Score; Cycle 20 Day 116.67 ± 23.11310.22 ± 15.915
Nausea and Vomiting Score; Cycle 21 Day 112.82 ± 20.7147.74 ± 12.408
Nausea and Vomiting Score; Cycle 22 Day 17.02 ± 11.5418.64 ± 13.374
Nausea and Vomiting Score; Cycle 23 Day 15.56 ± 12.0626.25 ± 11.849
Nausea and Vomiting Score; Cycle 24 Day 16.67 ± 13.8017.89 ± 17.004
Nausea and Vomiting Score; Cycle 25 Day 113.89 ± 21.1222.08 ± 8.333
Nausea and Vomiting Score; Cycle 26 Day 14.17 ± 7.71514.10 ± 24.387
Nausea and Vomiting Score; Cycle 27 Day 15.56 ± 13.60816.67 ± 28.868
Nausea and Vomiting Score; Cycle 28 Day 112.50 ± 15.9578.33 ± 20.412
Nausea and Vomiting Score; Cycle 29 Day 116.67 ± 13.6080 ± 0
Nausea and Vomiting Score; Cycle 30 Day 18.33 ± 16.6670
Nausea and Vomiting Score; Cycle 31 Day 116.67—
Nausea and Vomiting Score; Off-treatment Visit13.33 ± 22.5646.76 ± 13.207
Pain Score; Baseline23.39 ± 25.41023.77 ± 26.323
Pain Score; Cycle 2 Day 126.79 ± 25.85027.04 ± 23.862
Pain Score; Cycle 3 Day 127.63 ± 24.10325 ± 24.046
Pain Score; Cycle 4 Day 126.67 ± 24.78822.87 ± 21.486
Pain Score; Cycle 5 Day 129.04 ± 26.80522.97 ± 22.314
Pain Score; Cycle 6 Day 126.29 ± 24.88722.50 ± 25.716
Pain Score; Cycle 7 Day 128.04 ± 23.18923.65 ± 22.142
Pain Score; Cycle 8 Day 127.38 ± 23.72223.20 ± 24.949
Pain Score; Cycle 9 Day 127.11 ± 23.39321.01 ± 20.053
Pain Score; Cycle 10 Day 126.95 ± 22.60319.33 ± 18.792
Pain Score; Cycle 11 Day 127.29 ± 22.31918.06 ± 20.508
Pain Score; Cycle 12 Day 126.41 ± 21.01818.55 ± 19.814
Pain Score; Cycle 13 Day 124.40 ± 20.09218.48 ± 20.203
Pain Score; Cycle 14 Day 122.11 ± 22.66616.04 ± 19.601
Pain Score; Cycle 15 Day 124.24 ± 23.96617.65 ± 18.078
Pain Score; Cycle 16 Day 129.67 ± 25.41718.44 ± 20.628
Pain Score; Cycle 17 Day 127.78 ± 25.19817.50 ± 19.954
Pain Score; Cycle 18 Day 125.27 ± 20.12516.67 ± 18.803
Pain Score; Cycle 19 Day 131.48 ± 23.26619.61 ± 22.274
Pain Score; Cycle 20 Day 129.63 ± 23.26619.35 ± 21.558
Pain Score; Cycle 21 Day 126.92 ± 23.13117.86 ± 21.721
Pain Score; Cycle 22 Day 123.68 ± 17.84322.84 ± 24.085
Pain Score; Cycle 23 Day 121.11 ± 14.72918.06 ± 23.527
Pain Score; Cycle 24 Day 122.22 ± 20.57414.91 ± 19.160
Pain Score; Cycle 25 Day 127.78 ± 23.92515.63 ± 19.691
Pain Score; Cycle 26 Day 127.08 ± 21.70821.79 ± 27.542
Pain Score; Cycle 27 Day 125 ± 20.41211.90 ± 24.934
Pain Score; Cycle 28 Day 125 ± 21.5172.78 ± 6.804
Pain Score; Cycle 29 Day 125 ± 21.5176.67 ± 14.907
Pain Score; Cycle 30 Day 125 ± 16.6670
Pain Score; Cycle 31 Day 133.33—
Pain Score; Off-treatment Visit28.33 ± 27.35427.70 ± 28.171
Dyspnea Score; Baseline21.18 ± 25.56222.22 ± 26.006
Dyspnea Score; Cycle 2 Day 118.90 ± 24.24819.56 ± 23.865
Dyspnea Score; Cycle 3 Day 120.63 ± 24.15519.72 ± 23.871
Dyspnea Score; Cycle 4 Day 119.90 ± 24.22417.52 ± 20.643
Dyspnea Score; Cycle 5 Day 119.16 ± 23.20115.75 ± 20.925
Dyspnea Score; Cycle 6 Day 116.67 ± 21.10418.89 ± 23.957
Dyspnea Score; Cycle 7 Day 119.37 ± 23.92215.87 ± 21.728
Dyspnea Score; Cycle 8 Day 119.24 ± 23.48914.09 ± 20.319
Dyspnea Score; Cycle 9 Day 115.93 ± 20.74014.49 ± 21.712
Dyspnea Score; Cycle 10 Day 117.92 ± 21.83211.56 ± 19.369
Dyspnea Score; Cycle 11 Day 118.63 ± 23.31015.02 ± 23.764
Dyspnea Score; Cycle 12 Day 113.54 ± 21.99812.90 ± 22.057
Dyspnea Score; Cycle 13 Day 113.69 ± 20.86710.91 ± 20.341
Dyspnea Score; Cycle 14 Day 115.65 ± 21.62610.69 ± 20.437
Dyspnea Score; Cycle 15 Day 115.15 ± 19.62812.42 ± 21.040
Dyspnea Score; Cycle 16 Day 116.26 ± 22.5129.93 ± 16.904
Dyspnea Score; Cycle 17 Day 115.74 ± 20.29310 ± 20.255
Dyspnea Score; Cycle 18 Day 116.13 ± 20.85410.78 ± 17.829
Dyspnea Score; Cycle 19 Day 115.38 ± 21.5639.80 ± 17.465
Dyspnea Score; Cycle 20 Day 123.46 ± 20.28611.83 ± 16.212
Dyspnea Score; Cycle 21 Day 115.38 ± 16.9467.14 ± 13.929
Dyspnea Score; Cycle 22 Day 117.54 ± 20.39312.35 ± 18.829
Dyspnea Score; Cycle 23 Day 113.33 ± 21.08211.11 ± 18.822
Dyspnea Score; Cycle 24 Day 120 ± 21.08212.28 ± 16.520
Dyspnea Score; Cycle 25 Day 122.22 ± 29.5888.33 ± 14.907
Dyspnea Score; Cycle 26 Day 116.67 ± 17.81715.38 ± 22.008
Dyspnea Score; Cycle 27 Day 111.11 ± 17.21314.29 ± 17.817
Dyspnea Score; Cycle 28 Day 116.67 ± 19.24516.67 ± 18.257
Dyspnea Score; Cycle 29 Day 125 ± 16.66720 ± 18.257
Dyspnea Score; Cycle 30 Day 116.67 ± 19.2450
Dyspnea Score; Cycle 31 Day 133.33—
Dyspnea Score; Off-treatment Visit24.68 ± 27.25421.62 ± 28.898
Insomnia Score; Baseline23.08 ± 26.97222.84 ± 27.671
Insomnia Score; Cycle 2 Day 126.11 ± 27.03819.91 ± 25.386
Insomnia Score; Cycle 3 Day 130.39 ± 29.43523 ± 25.477
Insomnia Score; Cycle 4 Day 126.57 ± 28.05720.19 ± 24.036
Insomnia Score; Cycle 5 Day 123.02 ± 26.48722.05 ± 24.205
Insomnia Score; Cycle 6 Day 124.86 ± 26.95517.50 ± 22.019
Insomnia Score; Cycle 7 Day 125.08 ± 27.65120 ± 25.149
Insomnia Score; Cycle 8 Day 126.46 ± 28.84319.59 ± 25.346
Insomnia Score; Cycle 9 Day 125.56 ± 27.39216.67 ± 21.255
Insomnia Score; Cycle 10 Day 124.58 ± 25.84418.22 ± 22.789
Insomnia Score; Cycle 11 Day 124.02 ± 26.91817.37 ± 24.468
Insomnia Score; Cycle 12 Day 123.44 ± 23.51813.98 ± 22.216
Insomnia Score; Cycle 13 Day 121.43 ± 21.48913.33 ± 21.849
Insomnia Score; Cycle 14 Day 118.06 ± 23.77811.95 ± 21.774
Insomnia Score; Cycle 15 Day 118.94 ± 20.83216 ± 23.561
Insomnia Score; Cycle 16 Day 120.33 ± 20.92114.89 ± 21.768
Insomnia Score; Cycle 17 Day 117.59 ± 16.87713.33 ± 21.082
Insomnia Score; Cycle 18 Day 127.96 ± 25.95811.76 ± 19.903
Insomnia Score; Cycle 19 Day 124.69 ± 25.47413.73 ± 21.893
Insomnia Score; Cycle 20 Day 125.93 ± 25.03612.90 ± 20.507
Insomnia Score; Cycle 21 Day 123.08 ± 27.91910.71 ± 18.265
Insomnia Score; Cycle 22 Day 121.05 ± 19.9096.17 ± 16.111
Insomnia Score; Cycle 23 Day 126.67 ± 22.53711.11 ± 23.399
Insomnia Score; Cycle 24 Day 124.44 ± 26.62712.28 ± 19.909
Insomnia Score; Cycle 25 Day 116.67 ± 17.40812.50 ± 20.638
Insomnia Score; Cycle 26 Day 116.67 ± 17.81720.51 ± 32.026
Insomnia Score; Cycle 27 Day 122.22 ± 17.2139.52 ± 16.265
Insomnia Score; Cycle 28 Day 125 ± 16.66711.11 ± 17.213
Insomnia Score; Cycle 29 Day 125 ± 16.66713.33 ± 18.257
Insomnia Score; Cycle 30 Day 125 ± 16.6670
Insomnia Score; Cycle 31 Day 133.33—
Insomnia Score; Off-treatment Visit32.05 ± 32.43028.83 ± 31.850
Appetite Loss Score; Baseline15.79 ± 24.60618.31 ± 27.060
Appetite Loss Score; Cycle 2 Day 126.79 ± 31.12927.56 ± 32.020
Appetite Loss Score; Cycle 3 Day 131.97 ± 31.90529.81 ± 31.687
Appetite Loss Score; Cycle 4 Day 132.09 ± 31.23930.90 ± 32.749
Appetite Loss Score; Cycle 5 Day 130.47 ± 29.88130.67 ± 32.129
Appetite Loss Score; Cycle 6 Day 130.35 ± 31.36526.11 ± 29.996
Appetite Loss Score; Cycle 7 Day 129.28 ± 31.95626.98 ± 28.154
Appetite Loss Score; Cycle 8 Day 129.25 ± 31.48325.00 ± 26.491
Appetite Loss Score; Cycle 9 Day 129.30 ± 30.56525.36 ± 27.678
Appetite Loss Score; Cycle 10 Day 127.57 ± 29.71622.22 ± 22.815
Appetite Loss Score; Cycle 11 Day 124.15 ± 27.93822.07 ± 26.988
Appetite Loss Score; Cycle 12 Day 122.05 ± 24.49318.82 ± 25.336
Appetite Loss Score; Cycle 13 Day 123.21 ± 25.36217.28 ± 21.221
Appetite Loss Score; Cycle 14 Day 119.73 ± 24.45617.61 ± 24.111
Appetite Loss Score; Cycle 15 Day 117.42 ± 23.28224.18 ± 30.608
Appetite Loss Score; Cycle 16 Day 123.58 ± 27.12522.70 ± 27.014
Appetite Loss Score; Cycle 17 Day 120.37 ± 21.49622.50 ± 25.473
Appetite Loss Score; Cycle 18 Day 119.35 ± 22.40122.22 ± 24.533
Appetite Loss Score; Cycle 19 Day 119.75 ± 23.13020.59 ± 25.969
Appetite Loss Score; Cycle 20 Day 123.46 ± 25.84421.51 ± 30.488
Appetite Loss Score; Cycle 21 Day 123.08 ± 20.59015.48 ± 21.242
Appetite Loss Score; Cycle 22 Day 117.54 ± 20.39317.28 ± 25.099
Appetite Loss Score; Cycle 23 Day 117.78 ± 24.77420.83 ± 27.474
Appetite Loss Score; Cycle 24 Day 113.33 ± 24.56015.79 ± 25.744
Appetite Loss Score; Cycle 25 Day 119.44 ± 22.28518.75 ± 29.736
Appetite Loss Score; Cycle 26 Day 129.17 ± 27.81723.08 ± 34.385
Appetite Loss Score; Cycle 27 Day 116.67 ± 18.2579.52 ± 16.265
Appetite Loss Score; Cycle 28 Day 18.33 ± 16.66711.11 ± 17.213
Appetite Loss Score; Cycle 29 Day 116.67 ± 19.2450 ± 0
Appetite Loss Score; Cycle 30 Day 18.33 ± 16.6670
Appetite Loss Score; Cycle 31 Day 10—
Appetite Loss Score; Off-treatment Visit29.58 ± 31.82025.23 ± 32.082
Constipation Score; Baseline15.98 ± 24.87612.55 ± 23.501
Constipation Score; Cycle 2 Day 110.40 ± 20.27411.11 ± 21.035
Constipation Score; Cycle 3 Day 19.52 ± 20.64410.80 ± 20.456
Constipation Score; Cycle 4 Day 111.11 ± 21.9309.80 ± 19.081
Constipation Score; Cycle 5 Day 112.24 ± 20.4389.87 ± 19.411
Constipation Score; Cycle 6 Day 18.47 ± 16.9058.47 ± 19.090
Constipation Score; Cycle 7 Day 111.01 ± 22.8747.44 ± 16.785
Constipation Score; Cycle 8 Day 19.62 ± 18.6087.22 ± 14.614
Constipation Score; Cycle 9 Day 16.23 ± 15.6449.42 ± 19.967
Constipation Score; Cycle 10 Day 16.58 ± 13.3548.00 ± 18.042
Constipation Score; Cycle 11 Day 16.76 ± 15.7397.98 ± 18.227
Constipation Score; Cycle 12 Day 15.64 ± 13.9069.68 ± 18.492
Constipation Score; Cycle 13 Day 13.64 ± 12.2949.09 ± 18.653
Constipation Score; Cycle 14 Day 15.44 ± 14.1867.69 ± 16.978
Constipation Score; Cycle 15 Day 15.43 ± 17.7149.33 ± 19.095
Constipation Score; Cycle 16 Day 15.98 ± 16.8799.93 ± 18.277
Constipation Score; Cycle 17 Day 111.11 ± 22.5375.00 ± 12.054
Constipation Score; Cycle 18 Day 17.53 ± 14.1677.84 ± 16.532
Constipation Score; Cycle 19 Day 19.88 ± 18.0579.80 ± 20.969
Constipation Score; Cycle 20 Day 18.64 ± 17.5238.60 ± 22.718
Constipation Score; Cycle 21 Day 18.97 ± 17.7837.14 ± 16.623
Constipation Score; Cycle 22 Day 17.02 ± 13.9627.41 ± 19.245
Constipation Score; Cycle 23 Day 16.67 ± 13.80111.11 ± 21.234
Constipation Score; Cycle 24 Day 14.44 ± 17.2138.77 ± 21.779
Constipation Score; Cycle 25 Day 15.56 ± 12.97518.75 ± 29.736
Constipation Score; Cycle 26 Day 18.33 ± 15.43015.38 ± 25.875
Constipation Score; Cycle 27 Day 116.67 ± 27.8890 ± 0
Constipation Score; Cycle 28 Day 125.00 ± 31.9140 ± 0
Constipation Score; Cycle 29 Day 125.00 ± 31.9140 ± 0
Constipation Score; Cycle 30 Day 116.67 ± 33.3330
Constipation Score; Cycle 31 Day 133.33—
Constipation Score; Off-treatment Visit13.33 ± 23.48112.61 ± 21.863
Diarrhea Score; Baseline6.43 ± 15.0456.79 ± 15.823
Diarrhea Score; Cycle 2 Day 122.29 ± 29.57217.66 ± 26.333
Diarrhea Score; Cycle 3 Day 132.21 ± 30.85827.19 ± 32.023
Diarrhea Score; Cycle 4 Day 135.59 ± 33.63429.41 ± 28.991
Diarrhea Score; Cycle 5 Day 128.61 ± 28.08529.33 ± 29.207
Diarrhea Score; Cycle 6 Day 131.96 ± 30.55026.89 ± 27.541
Diarrhea Score; Cycle 7 Day 133.64 ± 31.88531.75 ± 27.881
Diarrhea Score; Cycle 8 Day 129.55 ± 28.81831.27 ± 28.793
Diarrhea Score; Cycle 9 Day 134.43 ± 33.12928.62 ± 28.637
Diarrhea Score; Cycle 10 Day 129.22 ± 29.99229.33 ± 25.088
Diarrhea Score; Cycle 11 Day 128.02 ± 28.36726.85 ± 26.619
Diarrhea Score; Cycle 12 Day 128.49 ± 31.27322.78 ± 23.363
Diarrhea Score; Cycle 13 Day 126.19 ± 28.22323.03 ± 25.558
Diarrhea Score; Cycle 14 Day 126.53 ± 25.44024.36 ± 22.008
Diarrhea Score; Cycle 15 Day 129.55 ± 29.82830.07 ± 26.038
Diarrhea Score; Cycle 16 Day 120.33 ± 27.76723.40 ± 21.886
Diarrhea Score; Cycle 17 Day 121.30 ± 24.10729.17 ± 28.432
Diarrhea Score; Cycle 18 Day 121.51 ± 25.16425.49 ± 23.296
Diarrhea Score; Cycle 19 Day 123.46 ± 28.96321.57 ± 21.528
Diarrhea Score; Cycle 20 Day 119.75 ± 23.13022.58 ± 23.392
Diarrhea Score; Cycle 21 Day 120.51 ± 26.79521.43 ± 18.624
Diarrhea Score; Cycle 22 Day 117.54 ± 20.39324.69 ± 19.812
Diarrhea Score; Cycle 23 Day 115.56 ± 17.21322.22 ± 16.051
Diarrhea Score; Cycle 24 Day 111.11 ± 16.26519.30 ± 16.909
Diarrhea Score; Cycle 25 Day 119.44 ± 22.28518.75 ± 17.078
Diarrhea Score; Cycle 26 Day 125.00 ± 29.54717.95 ± 17.296
Diarrhea Score; Cycle 27 Day 133.33 ± 21.08233.33 ± 19.245
Diarrhea Score; Cycle 28 Day 116.67 ± 19.24522.22 ± 17.213
Diarrhea Score; Cycle 29 Day 18.33 ± 16.66720.00 ± 18.257
Diarrhea Score; Cycle 30 Day 116.67 ± 19.2450
Diarrhea Score; Cycle 31 Day 133.33—
Diarrhea Score; Off-treatment Visit18.33 ± 25.38012.16 ± 19.565
Financial Difficulties Score; Baseline21.76 ± 28.38220.37 ± 29.076
Financial Difficulties Score; Cycle 2 Day 121.08 ± 28.17715.01 ± 24.852
Financial Difficulties Score; Cycle 3 Day 123.13 ± 27.20118.20 ± 27.451
Financial Difficulties Score; Cycle 4 Day 122.90 ± 27.76116.42 ± 25.113
Financial Difficulties Score; Cycle 5 Day 122.93 ± 28.21318.78 ± 29.058
Financial Difficulties Score; Cycle 6 Day 125.00 ± 27.41617.80 ± 25.666
Financial Difficulties Score; Cycle 7 Day 130.16 ± 31.86615.87 ± 24.062
Financial Difficulties Score; Cycle 8 Day 125.43 ± 29.17617.53 ± 24.576
Financial Difficulties Score; Cycle 9 Day 125.56 ± 30.00216.67 ± 23.440
Financial Difficulties Score; Cycle 10 Day 122.50 ± 27.95217.35 ± 24.913
Financial Difficulties Score; Cycle 11 Day 126.26 ± 30.10816.20 ± 24.382
Financial Difficulties Score; Cycle 12 Day 124.87 ± 28.06116.11 ± 24.156
Financial Difficulties Score; Cycle 13 Day 123.03 ± 26.35119.14 ± 25.577
Financial Difficulties Score; Cycle 14 Day 120.83 ± 22.41317.31 ± 25.127
Financial Difficulties Score; Cycle 15 Day 121.71 ± 27.10319.61 ± 26.813
Financial Difficulties Score; Cycle 16 Day 121.67 ± 25.65417.02 ± 24.937
Financial Difficulties Score; Cycle 17 Day 123.81 ± 27.50119.17 ± 27.099
Financial Difficulties Score; Cycle 18 Day 117.20 ± 18.99519.61 ± 28.566
Financial Difficulties Score; Cycle 19 Day 118.52 ± 19.24520.59 ± 28.444
Financial Difficulties Score; Cycle 20 Day 116.05 ± 21.42420.43 ± 30.644
Financial Difficulties Score; Cycle 21 Day 119.23 ± 21.44420.24 ± 27.725
Financial Difficulties Score; Cycle 22 Day 124.56 ± 24.45020.99 ± 29.451
Financial Difficulties Score; Cycle 23 Day 117.78 ± 17.21323.61 ± 31.819
Financial Difficulties Score; Cycle 24 Day 117.78 ± 21.33119.30 ± 25.618
Financial Difficulties Score; Cycle 25 Day 116.67 ± 22.47316.67 ± 24.343
Financial Difficulties Score; Cycle 26 Day 120.83 ± 24.80120.51 ± 32.026
Financial Difficulties Score; Cycle 27 Day 116.67 ± 18.2570 ± 0
Financial Difficulties Score; Cycle 28 Day 125.00 ± 16.6670 ± 0
Financial Difficulties Score; Cycle 29 Day 125.00 ± 16.6670 ± 0
Financial Difficulties Score; Cycle 30 Day 125.00 ± 16.6670
Financial Difficulties Score; Cycle 31 Day 10—
Financial Difficulties Score; Off-treatment Visit31.65 ± 32.42325.11 ± 30.318
SecondaryHRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Index Score and Visual Analogue Scale (VAS)

The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. The EQ-5D index was calculated by applying preference-based weights (tariffs) to the scores of the five health state dimensions. Index values can range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).

Time frame:
At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
Reported as:
Mean · score on a scale
HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Index Score and Visual Analogue Scale (VAS)
score on a scaleLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
EQ-5D Index Score; Baseline0.76 ± 0.2160.78 ± 0.232
EQ-5D Index Score; Cycle 2 Day 10.76 ± 0.1780.76 ± 0.230
EQ-5D Index Score; Cycle 3 Day 10.73 ± 0.2320.78 ± 0.239
EQ-5D Index Score; Cycle 4 Day 10.73 ± 0.2130.78 ± 0.236
EQ-5D Index Score; Cycle 5 Day 10.73 ± 0.2120.78 ± 0.199
EQ-5D Index Score; Cycle 6 Day 10.73 ± 0.2200.77 ± 0.225
EQ-5D Index Score; Cycle 7 Day 10.71 ± 0.2190.78 ± 0.196
EQ-5D Index Score; Cycle 8 Day 10.75 ± 0.1870.80 ± 0.187
EQ-5D Index Score; Cycle 9 Day 10.73 ± 0.1920.79 ± 0.192
EQ-5D Index Score; Cycle 10 Day 10.76 ± 0.1860.81 ± 0.177
EQ-5D Index Score; Cycle 11 Day 10.77 ± 0.1850.82 ± 0.82
EQ-5D Index Score; Cycle 12 Day 10.77 ± 0.1730.83 ± 0.161
EQ-5D Index Score; Cycle 13 Day 10.76 ± 0.1570.82 ± 0.179
EQ-5D Index Score; Cycle 14 Day 10.77 ± 0.1860.83 ± 0.163
EQ-5D Index Score; Cycle 15 Day 10.76 ± 0.1910.81 ± 0.165
EQ-5D Index Score; Cycle 16 Day 10.73 ± 0.1790.81 ± 0.212
EQ-5D Index Score; Cycle 17 Day 10.73 ± 0.2110.83 ± 0.158
EQ-5D Index Score; Cycle 18 Day 10.76 ± 0.1480.84 ± 0.177
EQ-5D Index Score; Cycle 19 Day 10.69 ± 0.2660.79 ± 0.205
EQ-5D Index Score; Cycle 20 Day 10.70 ± 0.2590.82 ± 0.167
EQ-5D Index Score; Cycle 21 Day 10.73 ± 0.2230.83 ± 0.180
EQ-5D Index Score; Cycle 22 Day 10.74 ± 0.1570.85 ± 0.173
EQ-5D Index Score; Cycle 23 Day 10.74 ± 0.1490.82 ± 0.242
EQ-5D Index Score; Cycle 24 Day 10.75 ± 0.1720.84 ± 0.156
EQ-5D Index Score; Cycle 25 Day 10.70 ± 0.2450.83 ± 0.175
EQ-5D Index Score; Cycle 26 Day 10.72 ± 0.1700.73 ± 0.438
EQ-5D Index Score; Cycle 27 Day 10.77 ± 0.1350.93 ± 0.117
EQ-5D Index Score; Cycle 28 Day 10.73 ± 0.1120.97 ± 0.067
EQ-5D Index Score; Cycle 29 Day 10.74 ± 0.1200.96 ± 0.075
EQ-5D Index Score; Cycle 30 Day 10.61 ± 0.3911
EQ-5D Index Score; Cycle 31 Day 10.87—
EQ-5D Index Score; Off-treatment Visit0.61 ± 0.3310.68 ± 0.314
EQ-VAS Score; Baseline68.57 ± 18.34870.01 ± 20.552
EQ-VAS Score; Cycle 2 Day 166.05 ± 18.53169.52 ± 19.155
EQ-VAS Score; Cycle 3 Day 166.22 ± 17.80470.71 ± 17.648
EQ-VAS Score; Cycle 4 Day 165.69 ± 18.26569.66 ± 17.784
EQ-VAS Score; Cycle 5 Day 165.86 ± 18.90870.30 ± 19.492
EQ-VAS Score; Cycle 6 Day 165.53 ± 20.02771.73 ± 17.366
EQ-VAS Score; Cycle 7 Day 165.74 ± 18.06370.39 ± 19.387
EQ-VAS Score; Cycle 8 Day 164.16 ± 18.96970.40 ± 20.130
EQ-VAS Score; Cycle 9 Day 165.51 ± 17.67069.92 ± 19.452
EQ-VAS Score; Cycle 10 Day 166.92 ± 17.74773.18 ± 20.167
EQ-VAS Score; Cycle 11 Day 167.74 ± 16.85073.21 ± 19.310
EQ-VAS Score; Cycle 12 Day 166.46 ± 18.68074.46 ± 17.139
EQ-VAS Score; Cycle 13 Day 165.64 ± 19.69074.35 ± 17.766
EQ-VAS Score; Cycle 14 Day 166.41 ± 17.83974.40 ± 17.678
EQ-VAS Score; Cycle 15 Day 167.05 ± 17.84772.58 ± 19.060
EQ-VAS Score; Cycle 16 Day 166.54 ± 18.11872.80 ± 17.733
EQ-VAS Score; Cycle 17 Day 165.78 ± 17.75573.80 ± 17.593
EQ-VAS Score; Cycle 18 Day 164.70 ± 18.17073.71 ± 16.665
EQ-VAS Score; Cycle 19 Day 162.15 ± 20.67671.76 ± 19.272
EQ-VAS Score; Cycle 20 Day 162.70 ± 19.77972.07 ± 19.293
EQ-VAS Score; Cycle 21 Day 162.12 ± 17.97476.46 ± 16.836
EQ-VAS Score; Cycle 22 Day 165.21 ± 14.72274.44 ± 16.860
EQ-VAS Score; Cycle 23 Day 167.73 ± 15.65073.67 ± 17.704
EQ-VAS Score; Cycle 24 Day 165.27 ± 19.38171.21 ± 21.212
EQ-VAS Score; Cycle 25 Day 160.58 ± 19.31372.81 ± 16.897
EQ-VAS Score; Cycle 26 Day 164.13 ± 16.31365.23 ± 25.652
EQ-VAS Score; Cycle 27 Day 161.83 ± 18.35777.43 ± 16.762
EQ-VAS Score; Cycle 28 Day 154.25 ± 8.69477.50 ± 20.907
EQ-VAS Score; Cycle 29 Day 152.75 ± 12.09374 ± 21.036
EQ-VAS Score; Cycle 30 Day 151.75 ± 11.29550
EQ-VAS Score; Cycle 31 Day 135—
EQ-VAS Score; Off-treatment Visit58.48 ± 23.51662.66 ± 22.252
SecondaryProgression-free Survival After Next Line of Therapy (PFS2)

PFS2, defined as the time from randomization to the date of PD after next line of therapy or death from any cause, whichever occurred first based on investigator assessment according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS2 was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% CI. As pre-specified in protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.

Time frame:
From the time of randomization to the date of PD after next line of therapy or death from any cause or the date of data cutoff for the primary analysis, whichever occurs first (up to 29 months)
Reported as:
Median · months
Progression-free Survival After Next Line of Therapy (PFS2)
monthsLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
Progression-free Survival After Next Line of Therapy (PFS2)18.2 (13.1 to 22.5)19.5 (14.1 to 23.8)

Adverse events

Collected over From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 14 mg + Everolimus 5 mg71/173 (41%)92/173 (53.2%)172/173 (99.4%)
Lenvatinib 18 mg + Everolimus 5 mg60/168 (35.7%)87/168 (51.8%)166/168 (98.8%)
Most frequent serious events
Showing 10 of 199
Most frequent serious events
EventLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
PneumoniaInfections and infestations13/1737/168
DiarrhoeaGastrointestinal disorders11/1736/168
Acute kidney injuryRenal and urinary disorders3/1736/168
VomitingGastrointestinal disorders6/1732/168
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1735/168
Blood creatinine increasedInvestigations2/1734/168
PyrexiaGeneral disorders4/1731/168
GastroenteritisInfections and infestations4/1731/168
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1733/168
EpistaxisRespiratory, thoracic and mediastinal disorders0/1733/168
Most frequent other events
Showing 10 of 60
Most frequent other events
EventLenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mg
DiarrhoeaGastrointestinal disorders117/173123/168
ProteinuriaRenal and urinary disorders40/17366/168
Decreased appetiteMetabolism and nutrition disorders64/17357/168
StomatitisGastrointestinal disorders61/17349/168
HypertensionVascular disorders54/17359/168
NauseaGastrointestinal disorders54/17352/168
FatigueGeneral disorders51/17350/168
VomitingGastrointestinal disorders41/17343/168
Weight decreasedInvestigations36/17341/168
AstheniaGeneral disorders42/17339/168

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Lenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mgTotal
Mean60.5 ± 9.5961.5 ± 9.9061.0 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mgTotal
Female394281
Male133129262
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mgTotal
Hispanic or Latino4812
Not Hispanic or Latino168163331
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 14 mg + Everolimus 5 mgLenvatinib 18 mg + Everolimus 5 mgTotal
American Indian or Alaska Native000
Asian332760
Native Hawaiian or Other Pacific Islander000
Black or African American000
White137140277
More than one race000
Unknown or Not Reported246
08

Study locations

93 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Innovative Clinical Research Institute, LLC
    Whittier, California 90603, United States
  • Baptist Health Medical Group Oncology, LLC - US Oncology
    Miami, Florida 33143, United States
  • Optimal Research
    Honolulu, Hawaii 96819, United States
  • Oklahoma Cancer Specialist and Research Institute , LLC
    Tulsa, Oklahoma 74146, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Texas Oncology PA - US Oncology
    Fort Worth, Texas 76104, United States
  • Macquarie University
    Macquarie Park, New South Wales, Australia
  • Northern Cancer Institute, Saint Leonards
    Saint Leonards, New South Wales, Australia
  • Adelaide Cancer Center
    Kurralta Park, South Australia, Australia
  • Sunshine Hospital
    Saint Albans, Victoria, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia, Australia
  • Alberta Health Service - Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • British Columbia Cancer Agency
    Kelowna, British Columbia V1Y 5L3, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6A 4L6, Canada
  • Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Research Institute- University of Toronto
    Toronto, Ontario M4N 3M5, Canada
  • Sir Mortimer B Davis Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Masarykuv onkologicky ustav
    Brno, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, Czechia
  • Fakultni nemocnice v Motole
    Prague, Czechia
  • Nemocnice Na Bulovce
    Prague, Czechia
  • Helsingin Yliopistollinen Keskussairaala
    Helsinki, Finland
  • Tampereen yliopistollinen sairaala
    Tampere, Finland
  • Turun Yliopistollinen Keskussairaala
    Turku, Finland
  • Vaasan Keskussairaala
    Vaasa, Finland
  • Alexandra Hospital
    Athens, Greece
  • Metropolitan hospital
    Athens, Greece
  • University General Hospital of Patras
    Patras, Greece
  • Interbalkan Medical Center of Thessaloniki
    Pylaia, Greece
  • EUROMEDICA General Clinic of Thessaloniki
    Thessaloniki, Greece
  • Papageorgiou General Hospital of Thessaloniki
    Thessaloniki, Greece
  • IRCCS Istituto Nazionale dei Tumori
    Milano, Lombardia, Italy
  • Presidio Ospedaliero San Donato
    Arezzo, 52100, Italy
  • AORN A Cardarelli
    Napoli, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 00152, Italy
  • National Cancer Center
    Goyang-si, Gyeonggido, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Chŏnam, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Severance Hospital - Yonsei University Health System
    Seoul, Korea, Republic of
  • The Catholic University of Korea, Seoul Saint Mary's Hospital
    Seoul, Korea, Republic of
  • Hagaziekenhuis
    Den Haag, Netherlands
  • MC Haaglanden
    Den Haag, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, Netherlands
  • Szpital Specjalistyczny w Brzozowie
    Brzozow, Poland
  • Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii
    Gdansk, Poland
  • NZOZ Vesalius
    Krakow, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, Poland
  • Centrum Onkologii Ziemi Lubelskiej
    Lublin, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Opolskie Centrum Onkologii
    Opole, Poland
  • Mrukmed. Lekarz Beata Madej-Mruk i Partner. Spolka Partnerska
    Rzeszow, Poland
  • MAGODENT Sp. z o.o. Szpital Elblaska
    Warszawa, Poland
  • Centro Hospitalar E Universitário de Coimbra EPE
    Coimbra, Portugal
  • Champalimaud Cancer Center
    Lisboa, Portugal
  • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
    Lisbon, Portugal
  • Centro Hospitalar do Porto - Hospital de Santo António
    Porto, Portugal
  • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
    Porto, Portugal
  • Medisprof SRL
    Cluj-Napoca, Romania
  • Prof Dr I Chiricuta Institute of Oncology
    Cluj-Napoca, Romania
  • Oncology Center Sfantul Nectarie
    Craiova, Romania
  • Oncocenter Clinical Oncology
    Timisoara, Romania
  • Altay Regional Oncology Center
    Barnaul, Russian Federation
  • Chelyabinsk Regional Clinical Oncology Dispensary
    Chelyabinsk, Russian Federation
  • Central Clinical Hospital With Polyclinic of President Administration of RF
    Moscow, Russian Federation
  • Moscow City Oncology Hospital #62
    Moscow, Russian Federation
  • Moscow Scientific Research Oncology Institute P.A. Herzen
    Moscow, Russian Federation
  • Federal State Institution Medical Radiology Research Center
    Obninsk, Russian Federation
  • Clinical Oncology Dispensary
    Omsk, Russian Federation
  • Regional Clinical Oncology Hospital
    Yaroslavl, Russian Federation
  • Hospital Universitario A Coruna
    A Coruna, Spain
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, Spain
  • C.H. Regional Reina Sofia
    Cordoba, Spain
  • ICO l'Hospitalet - Hospital Duran i Reynals
    Hospitalet de Llobregat, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • MD Anderson Cancer Center Madrid
    Madrid, Spain
  • Hospital Universitario Son Espases
    Palma de Mallorca, Spain
  • Clinica Universidad Navarra
    Pamplona, Spain
  • Fundacion Instituto Valenciano de Oncologia
    Valencia, Spain
  • China Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
  • Beatson West of Scotland Cancer Centre
    Glasgow, United Kingdom
  • Christie Hospital
    Manchester, United Kingdom
  • Mount Vernon Hospital
    Northwood, United Kingdom
  • Singleton Hospital
    Swansea, United Kingdom
09

References and documents

Publications

  • Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142. PubMed 35881028 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Feb 2020, 29 months.

Results were first posted in Mar 2021, 1 year after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 29 months is below that.

Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2017
First posted
Jun 2, 2017
StartActual
Aug 17, 2017
Primary completionActual
Feb 14, 2020
CompletionActual
Jun 20, 2024
Results first posted
Mar 5, 2021
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03173560
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 2, 2017
Start date
Aug 17, 2017
Primary completion
Feb 14, 2020
Completion
Jun 20, 2024
Results posted
Mar 5, 2021
Last update
Apr 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion